Depression and substance use disorders: Clinical comorbidity and shared neurobiology

Int Rev Neurobiol. 2021:157:245-309. doi: 10.1016/bs.irn.2020.09.004. Epub 2020 Nov 17.

Abstract

Mood disorders, including major depressive disorder (MDD), are the most prevalent psychiatric illnesses, and pose an incredible burden to society, both in terms of disability and in terms of costs associated with medical care and lost work time. MDD has extremely high rates of comorbidity with substance use disorders (SUD) as many of the same neurobiological circuits and molecular mechanisms regulate the reward pathways disrupted in both conditions. MDD may induce SUDs, SUD may contribute to MDD development, or underlying vulnerabilities and common life experience may confer risk to developing both conditions. In this chapter we explore theories of MDD and SUD comorbidity, the neurobiological underpinnings of depression, overlapping cellular and molecular pathways for both conditions, and current treatment approaches for these comorbid conditions.

Keywords: Addiction; BDNF; Comorbidity; Depression; NAc; PFC; VTA; ΔFOSB.

MeSH terms

  • Comorbidity
  • Depressive Disorder, Major* / epidemiology
  • Depressive Disorder, Major* / physiopathology
  • Humans
  • Substance-Related Disorders* / epidemiology
  • Substance-Related Disorders* / physiopathology